The Overexpression of KIT Proto-Oncogene in Acute Leukemic Cells Is Not Necessarily Caused by the Gene Mutation
暂无分享,去创建一个
[1] S. Corey,et al. Dasatinib Inhibits the Growth of Molecularly Heterogeneous Myeloid Leukemias , 2010, Clinical Cancer Research.
[2] M. Heuser,et al. An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. , 2010, Leukemia research.
[3] S. Baker,et al. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia , 2008, Molecular Cancer Therapeutics.
[4] H. Döhner,et al. Results of a multicenter phase II trial for older patients with c‐Kit‐positive acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (HR‐MDS) using low‐dose Ara‐C and Imatinib , 2007, Cancer.
[5] C. Auewarakul,et al. C-kit receptor tyrosine kinase (CD117) expression and its positive predictive value for the diagnosis of Thai adult acute myeloid leukemia , 2006, Annals of Hematology.
[6] H. Kantarjian,et al. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. , 2005, Leukemia research.
[7] H. Mitsuya,et al. Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation , 2005, Leukemia.
[8] J. Kononen,et al. Prevalence of KIT expression in human tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Marx,et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. , 2004, Blood.
[10] Yong-kun Wei,et al. C-kit gene mutation in human gastrointestinal stromal tumors. , 2004, World journal of gastroenterology.
[11] E. Estey,et al. C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. , 2004, Leukemia research.
[12] I. Bernstein,et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. , 2003, Blood.
[13] H. Moch,et al. KIT in ovarian carcinoma: disillusion about a potential therapeutic target. , 2003, Journal of the National Cancer Institute.
[14] H. Kantarjian,et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high‐risk myelodysplastic syndrome, and myeloproliferative disorders , 2003, Cancer.
[15] A. Marx,et al. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. , 2003, Blood.
[16] L. Ashman,et al. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. , 2002, Molecular cancer therapeutics.
[17] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[18] L. Nelson,et al. Investigation of KIT gene mutations in women with 46,XX spontaneous premature ovarian failure , 2002, BMC women's health.
[19] C. J. Chen,et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.
[20] Y. Ma,et al. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. , 2001, Leukemia research.
[21] R. Arceci,et al. Activating Mutations of c-Kit at Codon 816 Confer Drug Resistance in Human Leukemia Cells , 2001, Leukemia & lymphoma.
[22] L. Sobin,et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. , 2000, The American journal of pathology.
[23] B. Druker,et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.
[24] J. Reilly,et al. c‐kit proto‐oncogene exon 8 in‐frame deletion plus insertion mutations in acute myeloid leukaemia , 1999, British journal of haematology.
[25] N. Sepp,et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. , 1998, The Journal of investigative dermatology.
[26] T. Suda,et al. Analysis of C-KIT, TIE and HTK expression on leukemic cells using flow cytometry: a preliminary report. , 1998, Leukemia research.
[27] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[28] L. Larizza,et al. A novel potentially diagnostic polymorphism (4894 A/C) in exon 10 of the human c-kit proto-oncogene. , 1996, Molecular and cellular probes.
[29] G. Schmitz,et al. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. , 1996, Leukemia.
[30] Y. Suzuki,et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[31] Y. Satow,et al. c‐kit point mutation of extracellular domain in patients with myeloproliferative disorders , 1995, British journal of haematology.
[32] W. Gerald,et al. Expression of c-kit and kit ligand proteins in normal human tissues. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[33] M. Reuss-Borst,et al. AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. , 1994, Leukemia.
[34] E. Huang,et al. The kit-ligand (steel factor) and its receptor c-kit/W: pleiotropic roles in gametogenesis and melanogenesis. , 1993, Development (Cambridge, England). Supplement.
[35] L. Ashman,et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. , 1993, The Journal of clinical investigation.
[36] A. Ullrich,et al. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. , 1992, Cancer research.
[37] R. Spritz,et al. Organization and nucleotide sequence of the human KIT (mast/stem cell growth factor receptor) proto-oncogene. , 1992, Oncogene.
[38] S. Nishikawa,et al. Expression and function of c-kit in hemopoietic progenitor cells , 1991, The Journal of experimental medicine.
[39] L. Ashman,et al. Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. , 1991, Blood.
[40] A. Ullrich,et al. Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.
[41] L. Ashman,et al. Specificity of a mouse monoclonal antibody raised against acute myeloid leukaemia cells for mast cells in human mucosal and connective tissues , 1987, Immunology and cell biology.
[42] H. Gralnick,et al. Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.
[43] C. Bokemeyer,et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. , 2006, Cancer research.
[44] L. Ashman,et al. Expression of the YB 5 . BS Antigen ( cki t proto-oncogene product ) in Normal Human Bone Marrow , 2003 .
[45] R. Ward,et al. c‐kit mutations in gastrointestinal stromal tumours , 2002, Pathology.
[46] E. Jaffe,et al. Extranodal peripheral T-cell and NK-cell neoplasms. , 1999, American journal of clinical pathology.
[47] P. Musto,et al. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype. , 1998, Haematologica.
[48] A. Órfão,et al. The Reliability and Specificity of c-kit for the Diagnosis of Acute Myeloid Leukemias and Undifferentiated Leukemias , 1998 .
[49] E. Thiel,et al. Expression of the stem cell factor receptor C-KIT (CD117) in acute leukemias. , 1997, Haematologica.
[50] D. Catovsky,et al. C-kit receptor (CD117) expression in acute leukemia. , 1996 .
[51] L. Ashman,et al. Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. , 1994, Leukemia.
[52] C. Juttner,et al. Expression of a 150-kD cell surface antigen identified by monoclonal antibody YB5.B8 is associated with poor prognosis in acute non-lymphoblastic leukaemia. , 1988, Leukemia research.